If you are unable to view this newsletter, Please click here
Veticaltalk Pharma -  e-Newsletter

Layer-by-Layer Micro

and

Nano Drug Encapsulation with Eolyelectrolytes

Latest e-Newsletter www.pharmafocusasia.com | Archives | Advertise

Layer-by-Layer Micro and Nano Drug Encapsulation with Eolyelectrolytes


Progress and challenges
During LbL assembly oppositely charged polymers are electrostatically bound to one another producing insoluble nano-thick multilayers. The thickness of this multilayered film is controlled by the number of 2-3 nm polyelectrolyte bilayers that are deposited. Therefore, by simply alternating the adsorption of polycations and polyanions, thin organised films with a thickness ranging from of 5-500 nm that are precise to within a few nanometers, can be formed. In addition the composition of the film can be controlled and varied because a vast array of polyelectrolytes (synthetic or natural, such as polysaccharides and proteins) and even charged nanoparticles will form LbL coatings and shells. The only requirement is that the positive and negative components are alternated...


White Papers
..........................................................
media pack
..........................................................
Editorial Calender
..........................................................
News
The Changing Face of Beauty
January 27th, 2012
PARIS

The detailed 'Face Value' report explores all aspects of the aesthetic beauty procedure market, everything from attitudes toward cost to the necessity for clinically-tested safety and one of the most arresting research areas looks at the lengths women will go to in order to get the treatments they want. Despite the fact that economists predict that we are in a continued recession, 29% of women with experience in using facial injectables admit they would buy fewer or cheaper groceries to pay for a treatment while 31% say they would seek out a second or better paying job.
 
Press Releases
Ipsen Acknowledges Tanakan® Delisting in France
Jan 26th, 2012
Paris

Ipsen (Paris:IPN) (Euronext: IPN - ADR: IPSEY) acknowledges the French government’s decision to no longer reimburse Tanakan®, Tramisal® and Ginkogink®, presently manufactured at the industrial site of Dreux (France). This decision is linked to the French policy to reassess the reimbursement of a certain number of drugs by the French Social Security.
Events
Phacilitate Cell & Gene Therapy Forum 2012
Jan 30th - Feb 1st, 2012
The Grand Hyatt Washington, DC, United States
Phacilitate Ltd
anne@phacilitate.co.uk
Current Issue
Upcoming Issue

Mail us for
e-Book Access!

subscriptions@pharmafocusasia.com

Send to a friend | Archives | Mediapack | Advertise | Submit an Article

Support Staff : info@pharmafocusasia.com
Click here to Unsubscribe
Copyright © 2012. All Rights Reserved.